Smokers Who Quit Before Age 45 Significantly Reduce Risk of Lung Cancer

Industry Insight
Jun.09.2022
Smokers Who Quit Before Age 45 Significantly Reduce Risk of Lung Cancer
A new study conducted by the American Cancer Society highlighted that while quitting smoking reduces cancer risks at any age, doing so before the age of 45 nearly eliminates all risk.

Titled, “Association of Smoking Initiation and Cessation Across the Life Course and Cancer Mortality Prospective Study of 410 000 US Adults,” the study of over 400,000 Americans, found that smokers are three times more likely to die of a tobacco-related cancer than nonsmokers.

 

However, reported the researchers, quitting by age 45 reduces this risk by 89%, while for those who quit before they are 35, the risk is completely eliminated. On the other hand, quitting between ages 45-54 still reduces the risk by a significant 78%, while doing so between ages 55-64 cuts it by 56%.

 

The research team found that similarly, the age of smoking initiation also has an impact on cancer risk. People who started smoking before age 18 had at least three times the risk of dying from cancer, while those who started before age 10 had four times the risk.

 

Tobacco use behavior following a cancer diagnosis

 

Another recent study published in Annals of Internal Medicine, found that quitting smoking following a lung cancer diagnosis may prevent cancer recurrence and extend life. Titled, “Postdiagnosis Smoking Cessation and Reduced Risk for Lung Cancer Progression and Mortality,” the study was conducted by researchers from the International Agency for Research on Cancer, the specialized cancer agency of the World Health Organization, in collaboration with the N.N. Blokhin National Medical Research Centre of Oncology in Russia. The research team recruited 517 current adults who were current smokers when they were diagnosed with early-stage non-small cell lung cancer from 2 sites in Moscow, Russia.

 

At the start of the study the participants were interviewed to determine medical and lifestyle history, including tumor characteristics, and their tobacco use patterns. Each participant was followed each year for an average of 7 years in a bid to record any changes in their smoking behavior.

 

Of 517 lung cancer patients who were smokers when diagnosed, less than half quit (44.5%), and very few relapsed. The patients who quit smoking were more likely to live longer overall (6.6 years vs. 4.8. years), live longer without lung cancer (5.7 vs. 3.9 years) and have their disease progress at a slower rate (7.9 vs. 6 years).

 

In light of these findings, the research team concluded that quitting smoking after being diagnosed with early-stage non-small cell lung cancer may slow disease progression and decrease mortality.

 

Source:VapingPost

Australian Coalition Taskforce Calls for 80% Tobacco Tax Cut to Combat Illicit Market
Australian Coalition Taskforce Calls for 80% Tobacco Tax Cut to Combat Illicit Market
According to SGST on August 26, 2026, Australia’s Coalition Illegal Tobacco Taskforce released a report recommending an up to 80% cut in tobacco excise to reduce the appeal of the illicit tobacco market. The report claimed organised crime groups now control about 80% of Australia’s tobacco market and argued that high excise rates have widened the price gap between legal and illegal products. The recommendation remains a policy proposal and has not been adopted by the Australian government, which said its focus remains on enforcement, compliance and additional resources.
Aug.27
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Former Roche Neuroscience and Rare Diseases Communications Director Ria Kioupritzi Joins PMI as Scientific Affairs Director
Eleftheria (Ria) Kioupritzi, a biopharmaceutical professional with more than 15 years of experience, has joined Philip Morris International as Director Scientific Affairs within Corporate Affairs. She previously served at Roche as Senior Scientific Communications Director for Neuroscience and Rare Diseases and worked extensively in spinal muscular atrophy. Her earlier career also covered competitive intelligence, clinical and regulatory monitoring, pipeline development and launch preparation. During her time working in Roche's SMA field, Evrysdi passed through several U.S. FDA milestones, including its initial approval, an expanded indication for younger infants and approval of a tablet formulation. Public records do not show that Kioupritzi herself led the FDA submissions.
Sep.22
Malaysia Liquid Nicotine Returns to Poisons List, Leaving Vape Retail and RM354 Million Tax Collection in Legal Uncertainty
Malaysia Liquid Nicotine Returns to Poisons List, Leaving Vape Retail and RM354 Million Tax Collection in Legal Uncertainty
Malaysia’s withdrawal of its appeal in a landmark liquid-nicotine case has left a High Court ruling that struck down the 2023 nicotine exemption in force, bringing liquid and gel nicotine used in vaping products back under the Poisons Act 1952. At the same time, the Control of Smoking Products for Public Health Act 2024 continues to provide a regulatory framework for vaping products, creating uncertainty over retail sales, taxation and existing inventory. MPs are calling for nicotine vape sales and excise collection to stop, including refunds of more than RM354 million collected since 2023, while industry and consumer groups are asking the government to clarify the current legal position.
Sep.04
U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications
U.S. Ninth Circuit Upholds FDA Denial of MH Global’s Flavored Vape PMTA Applications
The U.S. Court of Appeals for the Ninth Circuit upheld the FDA’s denial of MH Global LLC’s applications to market flavored electronic nicotine delivery systems (ENDS). The court ruled that FDA’s comparative-efficacy framework, which requires applicants to show that flavored products provide greater cessation or switching benefits than tobacco-flavored alternatives, is consistent with the Tobacco Control Act’s “appropriate for the protection of the public health” standard. The court also found that FDA was not required to establish the framework through notice-and-comment rulemaking.
Aug.26
Canada Considers Easing Pharmacy-Only Nicotine Pouch Sales Rules, Potentially Reopening Convenience Store Channel
Canada Considers Easing Pharmacy-Only Nicotine Pouch Sales Rules, Potentially Reopening Convenience Store Channel
Canada's federal government is considering changes to current restrictions on where nicotine pouches can be sold, potentially allowing authorized products to return to convenience stores and other general retail channels, although no decision has been made. Since 2024, emerging nicotine replacement therapy products such as nicotine pouches have been largely restricted to behind-the-counter pharmacy sales. Health Canada, meanwhile, continues to recall unauthorized and higher-strength nicotine pouches, indicating that the current discussion concerns retail access for authorized products rather than a broad relaxation of nicotine pouch regulation.
Sep.14
Reynolds Puts Nearly 183,000 U.S. Contracted Outlets Under Age-Verification Rules, Covering 94% of Volume — Can It Shift an Unauthorized Vape Market?
Reynolds Puts Nearly 183,000 U.S. Contracted Outlets Under Age-Verification Rules, Covering 94% of Volume — Can It Shift an Unauthorized Vape Market?
Reynolds American says nearly 183,000 U.S. retail outlets are under contract, with its Retail Marketing Plan Contract covering about 94% of company volume and requiring point-of-sale age verification. The company combines those contracts with We Card, TruAge, NACS-linked infrastructure and POS integration, while enhanced Vuse Pro retail rules add ID scanning, purchase limits and stronger underage-sales accountability. The initial Vuse Pro rollout targets about 50,000 stores. The system is taking shape as unauthorized vapor products remain dominant in parts of the U.S. market: a 2026 study estimated they accounted for 69.4% of tracked brick-and-mortar e-cigarette dollar sales in December 2025.
Special Report
Oct.15